These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [The diagnosis and therapy of subclinical pituitary adenoma apoplexy]. Li JL; Yu CJ Zhonghua Wai Ke Za Zhi; 2005 Jul; 43(13):879-81. PubMed ID: 16083609 [TBL] [Abstract][Full Text] [Related]
29. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559 [TBL] [Abstract][Full Text] [Related]
30. Manifestation, management and outcome of subclinical pituitary adenoma apoplexy. Zhang F; Chen J; Lu Y; Ding X J Clin Neurosci; 2009 Oct; 16(10):1273-5. PubMed ID: 19577475 [TBL] [Abstract][Full Text] [Related]
31. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Colin P; Jovenin N; Delemer B; Caron J; Grulet H; Hecart AC; Lukas C; Bazin A; Bernard MH; Scherpereel B; Peruzzi P; Nakib I; Redon C; Rousseaux P Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):333-41. PubMed ID: 15890572 [TBL] [Abstract][Full Text] [Related]
32. The effect of growth hormone on pituitary tumour growth. Herring R; Russell-Jones D Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):365-8. PubMed ID: 20498595 [TBL] [Abstract][Full Text] [Related]
33. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623 [TBL] [Abstract][Full Text] [Related]
35. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy. van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181 [TBL] [Abstract][Full Text] [Related]
36. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence. Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101 [TBL] [Abstract][Full Text] [Related]
38. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Olsson DS; Buchfelder M; Schlaffer S; Bengtsson BA; Jakobsson KE; Johannsson G; Nilsson AG Eur J Endocrinol; 2009 Nov; 161(5):663-9. PubMed ID: 19734242 [TBL] [Abstract][Full Text] [Related]
39. Rapid enlargement of a residual craniopharyngioma during short-term growth hormone replacement. Niu DM; Guo WY; Pan HC; Wong TT Childs Nerv Syst; 2002 Apr; 18(3-4):164-5. PubMed ID: 11981627 [TBL] [Abstract][Full Text] [Related]
40. Prospective study of transsphenoidal pituitary surgery: is tumor volume a predictor for the residual tumor? Shrestha R; Qi L; Bao G; Wang MD Chin Med J (Engl); 2012 Jul; 125(14):2444-8. PubMed ID: 22882919 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]